Literature DB >> 26814501

The expanding landscape of diffusion-weighted MRI in prostate cancer.

Andreas G Wibmer1, Evis Sala1, Hedvig Hricak1, Hebert Alberto Vargas2.   

Abstract

The added value of diffusion-weighted magnetic resonance imaging (DW-MRI) for the detection, localization, and staging of primary prostate cancer has been extensively reported in original studies and meta-analyses. More recently, DW-MRI and related techniques have been used to noninvasively assess prostate cancer aggressiveness and estimate its biological behavior. The present article aims to summarize the potential applications of DW-MRI for noninvasive optimization of pretherapeutic risk assessment, patient management decisions, and evaluation of treatment response.

Entities:  

Keywords:  Diffusion-weighted imaging; Magnetic resonance imaging; Prognostic biomarker; Prostate cancer; Risk-assessment; Treatment response

Mesh：

Substances：

Year:  2016        PMID： 26814501      PMCID： PMC5458420          DOI： 10.1007/s00261-016-0646-6

Source DB:  PubMed          Journal:  Abdom Radiol (NY)


  72 in total

1.  Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: can ADC values contribute to assess the aggressiveness of prostate cancer?

Authors:  Yasushi Itou; Katsuyuki Nakanishi; Yoshifumi Narumi; Yasuko Nishizawa; Hideaki Tsukuma
Journal:  J Magn Reson Imaging       Date:  2011-01       Impact factor: 4.813

2.  Diffusion-weighted MRI of the prostate at 3.0 T: comparison of endorectal coil (ERC) MRI and phased-array coil (PAC) MRI-The impact of SNR on ADC measurement.

Authors:  Yousef Mazaheri; H Alberto Vargas; Gregory Nyman; Amita Shukla-Dave; Oguz Akin; Hedvig Hricak
Journal:  Eur J Radiol       Date:  2013-06-28       Impact factor: 3.528

3.  Tumor lesion diameter on diffusion weighted magnetic resonance imaging could help predict insignificant prostate cancer in patients eligible for active surveillance: preliminary analysis.

Authors:  Dong Hoon Lee; Kyo Chul Koo; Seung Hwan Lee; Koon Ho Rha; Young Deuk Choi; Sung Joon Hong; Byung Ha Chung
Journal:  J Urol       Date:  2013-05-28       Impact factor: 7.450

4.  Evaluation of diffusion-weighted MR imaging at inclusion in an active surveillance protocol for low-risk prostate cancer.

Authors:  Diederik M Somford; Caroline M Hoeks; Christina A Hulsbergen-van de Kaa; Thomas Hambrock; Jurgen J Fütterer; J Alfred Witjes; Chris H Bangma; Henk Vergunst; Geert A Smits; Jorg R Oddens; Inge M van Oort; Jelle O Barentsz
Journal:  Invest Radiol       Date:  2013-03       Impact factor: 6.016

5.  Whole-lesion apparent diffusion coefficient metrics as a marker of percentage Gleason 4 component within Gleason 7 prostate cancer at radical prostatectomy.

Authors:  Andrew B Rosenkrantz; Michael J Triolo; Jonathan Melamed; Henry Rusinek; Samir S Taneja; Fang-Ming Deng
Journal:  J Magn Reson Imaging       Date:  2014-02-25       Impact factor: 4.813

6.  Abnormal findings on multiparametric prostate magnetic resonance imaging predict subsequent biopsy upgrade in patients with low risk prostate cancer managed with active surveillance.

Authors:  Robert R Flavell; Antonio C Westphalen; Carmin Liang; Christopher C Sotto; Susan M Noworolski; Daniel B Vigneron; Zhen J Wang; John Kurhanewicz
Journal:  Abdom Imaging       Date:  2014-10

7.  Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 years.

Authors:  Mark A Preston; Adam S Feldman; John J Coen; W Scott McDougal; Matthew R Smith; Jonathan J Paly; Robert Carrasquillo; Chin-Lee Wu; Douglas M Dahl; Glen W Barrisford; Michael L Blute; Anthony I Zietman
Journal:  Urol Oncol       Date:  2015-06-06       Impact factor: 3.498

8.  The HIF-pathway inhibitor NSC-134754 induces metabolic changes and anti-tumour activity while maintaining vascular function.

Authors:  L C J Baker; J K R Boult; S Walker-Samuel; Y-L Chung; Y Jamin; M Ashcroft; S P Robinson
Journal:  Br J Cancer       Date:  2012-04-12       Impact factor: 7.640

9.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

10.  The role of 3-tesla diffusion-weighted magnetic resonance imaging in selecting prostate cancer patients for active surveillance.

Authors:  Chang Wook Jeong; Yong Hyun Park; Sung Ii Hwang; Sangchul Lee; Seong Jin Jeong; Sung Kyu Hong; Seok-Soo Byun; Hak Jong Lee; Sang Eun Lee
Journal:  Prostate Int       Date:  2014-12-30
View more
  2 in total

1.  Analysis of Diffusion-weighted MR Images Based on a Gamma Distribution Model to Differentiate Prostate Cancers with Different Gleason Score.

Authors:  Hiroko Tomita; Shigeyoshi Soga; Yohsuke Suyama; Keiichi Ito; Tomohiko Asano; Hiroshi Shinmoto
Journal:  Magn Reson Med Sci       Date:  2019-03-26       Impact factor: 2.471

Review 2.  Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials.

Authors:  Amita Shukla-Dave; Nancy A Obuchowski; Thomas L Chenevert; Sachin Jambawalikar; Lawrence H Schwartz; Dariya Malyarenko; Wei Huang; Susan M Noworolski; Robert J Young; Mark S Shiroishi; Harrison Kim; Catherine Coolens; Hendrik Laue; Caroline Chung; Mark Rosen; Michael Boss; Edward F Jackson
Journal:  J Magn Reson Imaging       Date:  2018-11-19       Impact factor: 5.119
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.